Literature DB >> 2440124

Influence of factor XIIIa activity on human whole blood clot lysis in vitro.

J W Jansen, F Haverkate, J Koopman, H K Nieuwenhuis, C Kluft, T A Boschman.   

Abstract

We studied the influence of Factor XIIIa (F XIIIa) activity on the lysis rate of fresh whole human blood clots, without using anticoagulants. Clotting was induced by exogenous thrombin, lysis by tissue-type Plasminogen Activator (t-PA) added before clotting. After various periods of time, lysis rates were determined by measuring the radioactivity in the supernatant of the clot originating from 125I-Fibrinogen added before clotting. Lysis rates were determined in the presence of endogenous F XIIIa and compared with those obtained after specific inhibition of F XIIIa activity. We used an IgG fraction of an antiserum quenching the F XIIIa activity. Addition of increasing amounts of the antibodies to normal blood resulted in a dramatic increase in clot lysis rate, concomitant with loss of F XIII activity. Lysis of blood clots from a patient with a congenital, homozygous, functional alpha 2-Antiplasmin (alpha 2-AP) deficiency (alpha 2-AP-Enschede) was not or slightly increased by the anti F XIII antibodies indicating that fibrin-fibrin crosslinking per se does not contribute essentially to resistance of the blood clot against fibrinolysis. Both active alpha 2-AP and F XIIIa are required for the major part of the F XIII-dependent resistance of whole blood clots against lysis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2440124

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

1.  Model thrombi formed under flow reveal the role of factor XIII-mediated cross-linking in resistance to fibrinolysis.

Authors:  N J Mutch; J S Koikkalainen; S R Fraser; K M Duthie; M Griffin; J Mitchell; H G Watson; N A Booth
Journal:  J Thromb Haemost       Date:  2010-09       Impact factor: 5.824

2.  Usefulness of HATCH score in the prediction of new-onset atrial fibrillation for Asians.

Authors:  Kazuyoshi Suenari; Tze-Fan Chao; Chia-Jen Liu; Yasuki Kihara; Tzeng-Ji Chen; Shih-Ann Chen
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

3.  Incorporation of α2-Plasmin Inhibitor into Fibrin Clots and Its Association with the Clinical Outcome of Acute Ischemic Stroke Patients.

Authors:  Zsuzsa Bagoly; Barbara Baráth; Rita Orbán-Kálmándi; István Szegedi; Réka Bogáti; Ferenc Sarkady; László Csiba; Éva Katona
Journal:  Biomolecules       Date:  2021-02-25

Review 4.  Fibrinolysis in Platelet Thrombi.

Authors:  Rahim Kanji; Ying X Gue; Vassilios Memtsas; Diana A Gorog
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923

5.  Impact of low coagulation factor XIII activity in patients with chronic subdural hematoma associated with cerebrospinal fluid hypovolemia: A retrospective study.

Authors:  Takafumi Shimogawa; Takato Morioka; Tetsuro Sayama; Tomoaki Akiyama; Sei Haga; Toshiyuki Amano; Yoshihiko Furuta; Kei Murao; Shuji Arakawa; Iwao Takeshita
Journal:  Surg Neurol Int       Date:  2017-08-14

Review 6.  Inhibition of Fibrinolysis by Coagulation Factor XIII.

Authors:  Dingeman C Rijken; Shirley Uitte de Willige
Journal:  Biomed Res Int       Date:  2017-07-06       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.